555 reports of this reaction
2.0% of all OMEGA 3 ACID ETHYL ESTERS reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for OMEGA 3 ACID ETHYL ESTERS, manufactured by Waylis Therapeutics LLC. There are 555 FDA adverse event reports linking OMEGA 3 ACID ETHYL ESTERS to DYSPNOEA. This represents approximately 2.0% of all 27,867 adverse event reports for this drug.
Patients taking OMEGA 3 ACID ETHYL ESTERS who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for OMEGA 3 ACID ETHYL ESTERS, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for OMEGA 3 ACID ETHYL ESTERS:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 555 FDA reports for OMEGA 3 ACID ETHYL ESTERS. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.0% of all adverse event reports for OMEGA 3 ACID ETHYL ESTERS, making it a notable side effect.
If you experience dyspnoea while taking OMEGA 3 ACID ETHYL ESTERS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.